Compared with anti-PD-1/PD-L1 monotherapy, the combined strategy of PD-1/PD-L1 inhibitors plus anti-VEGF agents achieved more clinical improvements for advanced HCC patients in ORR (0.26 vs. 0.21), DCR (0.75 vs. 0.59), and PFS (6.2 months vs. 4.19 months) according to the results of the meat analysis based on recent clinical trials (15). Here, VEGFA is linked to hepatocellular carcinoma.